Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer

International Journal of Biological Markers

Volumn 25, Issue 2, 2010, Pages 59-68

  Chen, Yan ^a   Zou, Tian Ning ^a   Wu, Zhi Ping ^a   Zhou, Yong Chun ^a   Gu, Yu Lan ^a   Liu, Xin ^a   Jin, Cong Guo ^a   Wang, Xi Cai ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CEA; Circulating tumor cells; CK19; Mammaglobin; RT PCR

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MAMMAGLOBIN; MESSENGER RNA; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; MAMMAGLOBIN A; SCGB2A2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; UTEROGLOBIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD DONOR; BLOOD SAMPLING; BONE SCINTISCANNING; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CELL STRAIN MCF 7; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; DISEASE MARKER; EARLY CANCER; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREDICTIVE VALIDITY; PREMENOPAUSE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA EXTRACTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; BLOOD; BREAST NEOPLASMS; CARCINOMA; CHEMISTRY; DISEASE COURSE; EARLY DIAGNOSIS; EVALUATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; PROCEDURES; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; AGED; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KERATIN-19; MAMMAGLOBIN A; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTEROGLOBIN;

EID: 77954914489     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500201     Document Type: Article

References (36)

1. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 3404-12.
2. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802. (Pubitemid 41215488)
3. Vincent-Salomon A, Bidard FC, Pierga JY. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol 2008; 61: 570-6. (Pubitemid 351678207)
4. Tjensvoll K, Gilje B, Oltedal S, et al. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow. Breast Cancer Res Treat 2009; 116: 329-38.
5. Sledge GW, Jr. Circulating tumor cells in breast cancer: blood will tell. Clin Cancer Res 2006; 12: 6321-2.
6. Ignatiadis M, Kallergi G, Ntoulia M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008; 14: 2593-600.
7. Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009; 27: 2177-84.
8. Mercatali L, Valenti V, Calistri D, et al. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann Oncol 2006; 17: 424-8. (Pubitemid 43329578)
9. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
10. Xenidis N PM, Kafousi M, Apostolaki S, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24: 3756-62.
11. Pierga JY, Bidard FC, Denis MG, de Cremoux P. Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years. Mol Oncol 2007; 1: 267-8. (Pubitemid 350181647)
12. Marrakchi R, Ouerhani S, Benammar S, et al. Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer. Int J Biol Markers 2008; 23: 238-43.
13. Daskalaki A, Agelaki S, Perraki M, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009; 101: 589-97.
14. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56: 860-5.
15. Span PN, Sweep FC. Mammaglobin as molecular marker of breast cancer (micro)metastases. Clin Cancer Res 2005; 11: 7043; author reply 7044.
16. Roncella S, Ferro P, Bacigalupo B, et al. Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. Diagn Mol Pathol 2008; 17: 28-33.
17. Dono M, Ferro P, Benedetti L, et al. Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. J Neurooncol 2009; 91: 295-8.
18. Zuo L, Li L, Wang Q, Fleming TP, You S. Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer Cell Int 2009; 9: 8.
19. Marques AR, Teixeira E, Diamond J, et al. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat 2009; 114: 223-32.
20. Jotsuka T, Okumura Y, Nakano S, et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 2004; 135: 419-26.
21. Janku F, Srovnal J, Korinkova G, et al. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA. Neoplasma 2008; 55: 317-22.
22. International Union Against Cancer (UICC). TNM classification of malignant tumors, 5th edition. New York: John Wiley & Sons, Inc., 1997.
23. Tavassoli FA, Devilee P, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
24. Bosma AJ, Weigelt B, Lambrechts AC, et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 2002; 8: 1871-7. (Pubitemid 34633748)
25. Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999; 17: 2015-9. (Pubitemid 29318829)
26. Hongbo L, Xiaohui L, Hong K, Wei W, Yong Z. Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation. Clin Biochem 2007; 40: 562-6. (Pubitemid 46601421)
27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7. (Pubitemid 19032001)
28. Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D, Jirillo A. Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 2009; 76: 375-86.
29. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-40. (Pubitemid 351596394)
30. Raynor MP, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, Dobrovic A. Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol 2009; 2: 24.
31. Chen CC, Hou MF, Wang JY, et al. Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis. Cancer Lett 2006; 240: 279-88.
32. Shen C, Hu L, Xia L, Li Y. The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem 2009; 42: 194-200.
33. You F, Roberts LA, Kang SP, et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol 2008; 1: 2.
34. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008; 13: 447-51.
35. Glaves D, Huben RP, Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 1988; 57: 32-5. (Pubitemid 18067099)
36. Ntoulia M SA, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006; 39: 879-87. (Pubitemid 44363084)